2-{[1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]thio}-4-methoxy-N-(4-methyl-1,3-thiazol-2-yl)butanamide | 1207760-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-{[1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]thio}-4-methoxy-N-(4-methyl-1,3-thiazol-2-yl)butanamide
• 英文别名: 2-[1-(2-chlorophenyl)pyrazolo[3,4-d]pyrimidin-4-yl]sulfanyl-4-methoxy-N-(4-methyl-1,3-thiazol-2-yl)butanamide
• CAS: 1207760-91-5
• 化学式: C₂₀H₁₉ClN₆O₂S₂
• 分子量: 474.995
• InChiKey: IMPYIOYTNMCHNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  148
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  5-氨基-1-(2-氯苯基)-1H-吡唑-4-甲腈 在 劳森试剂 、 硫酸 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-{[1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]thio}-4-methoxy-N-(4-methyl-1,3-thiazol-2-yl)butanamide
  参考文献：
  名称：

  The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold

  摘要：

  Glucokinase is a key enzyme in glucose homeostasis since it phosphorylates glucose to give glucose-6-phosphate, which is the first step in glycolysis. GK activators have been proven to lower blood-glucose, and therefore have potential as treatments for type 2 diabetes. Here the discovery of pyrazolopyrimidine GKAs is reported. An original singleton hit from a high-throughput screen with micromolar levels of potency was optimised to give compounds with nanomolar activities. Key steps in this success were the introduction of an extra side-chain, which increased potency, and changing the linking functionality from a thioether to an ether, which led to improved potency and lipophilic ligand efficiency. This also led to more stable compounds with improved profiles in biological assays. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.090

文献信息

• THERAPEUTIC AGENTS 414
  申请人：BENNETT Stuart Norman Lile

  公开号：US20100093757A1

  公开（公告）日：2010-04-15

  A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

  化合物Formula (I)在通过葡萄糖激酶（GLK或GK）介导的疾病或医疗状况的治疗或预防中很有用，导致胰岛素分泌的葡萄糖阈值降低。
• US8143263B2
  申请人：——

  公开号：US8143263B2

  公开（公告）日：2012-03-27
• [EN] THERAPEUTIC AGENTS 414<br/>[FR] AGENTS THÉRAPEUTIQUES 414
  申请人：ASTRAZENECA AB

  公开号：WO2010015849A2

  公开（公告）日：2010-02-11

  A compound of Formula (I) is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.